{
  "abstract": "Obstructive sleep apnoea (OSA) is increasingly recognised as a highly heterogeneous disorder.1 Drivers of the disease process are various and include anatomical traits such as upper airway narrowing related to the interaction of craniofacial structure and obesity, as well as physiological traits such as low arousal threshold (a low level of respiratory stimulus required to trigger arousal), high loop gain (oversensitive respiratory control system) and reduced upper airway muscle responsiveness (diminished ability to prevent airway collapse).2",
  "authors": [
    {
      "affiliations": [
        "Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia",
        "Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia"
      ],
      "name": "Peter A Cistulli"
    },
    {
      "affiliations": [
        "Charles Perkins Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia",
        "Department of Respiratory and Sleep Medicine, Royal North Shore Hospital, St Leonards, New South Wales, Australia"
      ],
      "name": "Anna Mohammadieh"
    }
  ],
  "title": "Targeting OSA endotypes with drug therapy: dream or reality?",
  "uid": "769a9829-8cbc-589f-a296-c889c16ff5b2"
}